Integration of Pharmaceutical Discovery and Development: Case Histories

Borchardt, Ronald T. (Editor)/ Freidinger, Roger M. (Editor)/ Sawyer, Tomi K. (Editor)/ Smith, Philip L. (Editor)

ISBN 10: 0306457431 / ISBN 13: 9780306457432

Published by Plenum Pub Corp, 1998

About this Item

607 pages. 9.50x6.25x1.50 inches. In Stock.

Seller Inventory # x-0306457431

Bibliographic Details

• Title: Integration of Pharmaceutical Discovery and Development: Case Histories
• Publisher: Plenum Pub Corp
• Publication Date: 1998
• Language: English
• ISBN 10: 0306457431
• ISBN 13: 9780306457432
• Binding: Hardcover
• Condition: Brand New
• Weight: 1.12 kilograms

About this title

Synopsis

In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Therefore, in the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new str- egy required medicinal chemists to design drug candidates with structural f- tures that optimized pharmacological (e. g. , high affinity and specificity for the target receptor), pharmaceutical (e. g. , solubility and chemical stability), bioph- maceutical (e. g. , cell membrane permeability), and metabolic/pharmacokinetic (e. g. , metabolic stability, clearance, and protein binding) properties. Successful implementation of this strategy requires a multidisciplinary team effort, incl- ing scientists from drug design (e. g. , medicinal chemists, cell biologists, en- mologists, pharmacologists) and drug development (e. g. , analytical chemists, pharmaceutical scientists, physiologists, and molecular biologists representing the disciplines of pharmaceutics, biopharmaceutics, and pharmacokinetics/drug metabolism). With this new, highly integrated approach to drug design now widely utilized by the pharmaceutical industry, the editors of this book have provided the sci- tific community with case histories to illustrate the nature of the interdisciplinary interactions necessary to successfully implement this new approach to drug d- covery. In the first chapter, Ralph Hirschmann provides a historical perspective of why this paradigm shift in drug discovery has occurred.